Hims & Hers shares jumped this week as hims stock rose roughly 49 percent over five trading sessions, reversing earlier losses. The move followed an announcement that the FDA will review whether to remove a set of 12 peptides from a restricted list, a change that could reopen compounding and manufacturing opportunities.
Health Secretary Robert F. Kennedy Jr. publicly supported the peptide review and framed the action as restoring science and accountability, comments that helped focus investor attention on peptide markets. Hims previously bought a California peptide manufacturing facility and has signaled plans to launch a longevity specialty product line featuring peptides, coenzymes and GLP treatments.
The other catalyst was a settlement with Novo Nordisk, ending a public legal dispute. Under the agreement Hims agreed to prioritize distribution of branded Wegovy injections and oral Wegovy through its platform, while Novo Nordisk dropped its lawsuit. The pact gives Hims a clear, sanctioned route into the branded GLP-1 market after an earlier messy breakup that involved accusations of promoting knockoff versions and regulatory pushback.
Financials Outlook And Operational Shifts
Investors will watch an upcoming quarterly report that analysts say will show profit pressure, with an expected steep year-over-year EPS decline. The company guided quarterly revenue in a specified range, while analysts flagged an expected EPS near six cents, reflecting heavier capital spending tied to manufacturing build-out and a pending acquisition of Eucalyptus.
Capital expenditures have risen sharply in recent quarters and free cash flow swung negative versus a prior positive result. Management reported annual revenue of $2.35 billion and said the business grew strongly on the back of compounded GLP-1 products. The company is guiding for lower overall growth as higher-margin compounded offerings give way to branded Wegovy distribution.
Hims built more than one million square feet of U.S. facility space, including sterile injectable capacity that aligns with weight loss and GLP-1 demand. The company reported more than 2.5 million subscribers, average monthly revenue per subscriber of $83, and subscriber growth of about 13 percent year-over-year. The Eucalyptus deal, if completed, would add more recurring revenue, with the target cited as having annual recurring revenue above $450 million.
